The company has reported a net income of $5.1m, or $0.12 per diluted share, against net income of $4.85m or $0.11 per diluted share, for the same period last year.
China Pharma’s income from operations was $5.34m, as compared to $4.83m for the same period prior year.
The company’s gross profit was $6.87m, as compared to $6.13m for the same period in 2010.
China Pharma chairman and CEO Zhilin Li said in 2011, they anticipate adding new higher-margin revenue streams to their upcoming new products, which should help offset pockets of margin pressure coming from higher raw material costs and more competitive pricing due to government reform policies.